Second- and Further-Line Therapy with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer in Daily Clinical Practice

Table 2

Progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and one-year survival in different erlotinib therapy lines.

	All lines (𝑛=84)	Second-line (𝑛=34)	Third-line (𝑛=36)	Fourth-line and more-line (𝑛=14)	𝑃 value
PFS (days)	83 (CI 70.0–96.0)	80 (CI 67.0–93.0)	89 (CI 58.6–119.4)	84 (55.8–112.2)	0.886^1
OS (months)	7 (CI 4.7–9.3)	7 (CI 4.1–9.9)	4 (CI 2.6–5.3)	9 (CI 1.34–16.7)	0.178^1
DCR	66.2%; (CI 54.3%–76.8%)	58.6%; (CI 38.9%–76.5%)	69.7%; (CI 51.3%–84.4%)	75%; (CI 42.8%–94.5%)	0.542^2
1-year survival rate	33%; (CI 22%–43%)	31%; (CI 14%–47%)	28%; (CI 13%–43%)	49%; (CI 22%–76%)	0.178^1

1log rank test.
²Chi² test.